A Study of Single and Repeated Doses of LY3556050 in Healthy Participants

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy

In brief

The main purpose of this study is to conduct blood tests to measure how much LY3556050 is in the bloodstream and to determine if any age, gender, or food effects exist. The study will also evaluate the safety of LY3556050. This is a 2-part study. In Part 1, single increasing doses of LY3556050 will be given orally and participants will be confined for a 5-day period. In Part 2, multiple increasing doses of LY3556050 will be given orally and participants will be confined for a 14-day period.

Key facts

Study ID

NCT05341102

Run by

Eli Lilly and Company

People needed

106

Starts

2016-09-14

Expected to finish

2017-06-02

Last updated by the study team

2022-04-22

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Are overtly healthy as determined by medical evaluation.
• Participants with a body mass index (BMI) of 18.0 to 35.0 kilograms per square meter (kg/m²) and have body weight of 50 kg or more.

You may not qualify if…

• Has any history of or active cardiac disease, including congestive heart failure, angina, any arrhythmia, or clinically significant findings on Electrocardiogram (ECG).
• Has diabetes mellitus, acromegaly, clinically active thyroid disease, or other active endocrinopathy.
• Has asthma or other severe respiratory disease.
• Is pregnant, lactating, or planning a pregnancy.
• Has active alcohol or substance abuse or history of alcohol or substance abuse within the 6 months prior to randomization.
• Any abnormal laboratory finding or vital signs outside specified parameters.

Where it is running

• Medpace Clinical Pharmacology, LLC — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.